AACR Data Highlights InNexus Preclinical Antibody Candidate.- Additional Presentations Underscore Potency, Binding Capabilities for Antibody Pipeline And Novel Technologies - SCOTTSDALE, Ariz., April 9 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. : IXS (Integrated XSeries Server) An x86-based xSeries server (motherboard and memory) from IBM that plugs into an iSeries or i5 midrange computer. Running Windows or Linux, the IXS shares disk storage, server management, user administration with its iSeries/i5 host. .V, http://www.ixsbio.com/), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL (Domino eXtensible Language) A version of XML for Domino-based data. An XSLT processor is used to convert DXL data to XML data for external use. See Lotus Notes. (TM)), announced today that the company will be presenting new data on its lead preclinical candidate DXL625 (CD20) for the prospective treatment of Non Hodgkin's Lymphoma (NHL NHL Non-Hodgkin's lymphoma, see there ) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver. "Preclinical data on DXL625 indicates the strong promise of this candidate as a prospective treatment for NHL and Chronic Lymphatic Leukemia (CLL CLL abbr. chronic lymphocytic leukemia CLL, n.pr See leukemia, chronic lymphocytic. CLL 1. Chronic lymphocytic leukemia 2. Cholesterol-lowering lipid ), and we anticipate starting clinical trials in the near term," said Dr. Thomas Kindt, Chief Scientific Officer of InNexus. "The AACR will also feature a scientific presentation on our novel, proprietary approach for creating 'programmed' self-binding properties into antibodies. The increased potency of the antibody resulting from this technique suggests a new way to enhance antibody performance." Jeff Morhet, Chairman and Chief Executive Officer of InNexus, said, "InNexus has executed a focused and accelerated development plan for DXL625, while efficiently discovering promising new therapeutic candidates and supportive technologies. InNexus remains a novel, and independent, 'pure-play' antibody development company--an unusual investment and commercial opportunity." InNexus' AACR presentations are titled, "A Novel High Avidity avidity /avid·i·ty/ (ah-vid´i-te) 1. the strength of an acid or base. 2. in immunology, an imprecise measure of the strength of antigen-antibody binding based on the rate at which the complex is formed. Cf. Anti-CD20 With Markedly Increased Cytotoxicity Shows No Systemic Toxicity In The Cynomolgus Monkey At A Dose 100-Fold Above The Anticipated Therapeutic Dose", (AACR# 1231) and "Oxidative Modification Of An Anti-CD20 Antibody Imparts Autophilic Binding Kinetics", (AACR# 1230). Posters and company representatives will also be available within the AACR Antibody and Antibody Targets Session from 1:00-5:00 PM on April 19th in Hall B-F, Poster Section 12. The posters will also be available via the InNexus website beginning April 19th. About InNexus InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com/. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements. CONTACT: Jeff Morhet, Chairman & Chief Executive Officer, or Dr. Thomas Kindt, Chief Scientific Officer, both of InNexus Biotechnology Inc., +1-480-862-7500 Web Site: http://www.ixsbio.com/ |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion